Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations

INTRODUCTION: Data on utilization and clinical outcomes of programmed cell death protein or programmed death-ligand 1 (PD-[L]1) inhibitors in NSCLC with uncommon oncogenic alterations is limited. METHODS: This retrospective study used a deidentified U.S. nationwide clinicogenomic database to select...

Descripción completa

Detalles Bibliográficos
Autores principales: Garassino, Marina C., Oskar, Sabine, Arunachalam, Ashwini, Zu, Ke, Kao, Yu-Han, Chen, Cai, Meng, Weilin, Pietanza, M. Catherine, Zhao, Bin, Aggarwal, Himani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514206/
https://www.ncbi.nlm.nih.gov/pubmed/37744307
http://dx.doi.org/10.1016/j.jtocrr.2023.100568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514206/
https://www.ncbi.nlm.nih.gov/pubmed/37744307
http://dx.doi.org/10.1016/j.jtocrr.2023.100568

Ejemplares similares